Meningococcal vaccine groups A C Y W-135 conjugate - Chongqing Zhifei Biological Products

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Chongqing Zhifei Biological Products

Alternative Names: A, C, Y, W135 meningococcal polysaccharide conjugate vaccine; Menwaycon

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Chongqing Zhifei Biological Products
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Meningococcal-group-Y-infections in China (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Meningococcal-group-A-infections in China (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Meningococcal-group-W-135-infections in China (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top